Intellia Therapeutics, Inc.

NTLA

$81.89

+268.91% (1 year change)

Avg closing price

Price range

Market Cap

$3.27 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$16.3 Million

Total revenue in the last quarter.

Net Income

-$32.4 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$2.30

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-28.19x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-33 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

211

The number of full time employees.

Revenue & Earnings

Balance Sheet

Intellia Therapeutics, Inc.

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.

News

Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com

Raymond James Stick to Their Buy Rating for Intellia Therapeutics

Investing.com Investing.com, 9 days ago
CRISPR Technology Market Growing Demand to Impact Revenue Share by 2030 | Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation

CRISPR Technology Market Growing Demand to Impact Revenue Share by 2030 | Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation

The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow fr...

OpenPR OpenPR, about 1 month ago
Intellia Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis

Intellia Therapeutics Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis

Intellia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily Stock Market Daily, 3 months ago